HALOZYME THERAPEUTICS INC
NASDAQ: HALO (Halozyme Therapeutics, Inc.)
Kemas kini terakhir: 13 jam lalu68.32
-0.20 (-0.29%)
| Penutupan Terdahulu | 68.52 |
| Buka | 68.52 |
| Jumlah Dagangan | 1,197,517 |
| Purata Dagangan (3B) | 1,599,100 |
| Modal Pasaran | 8,103,640,064 |
| Harga / Pendapatan (P/E TTM) | 23.97 |
| Harga / Pendapatan (P/E Ke hadapan) | 9.46 |
| Harga / Jualan (P/S) | 5.57 |
| Harga / Buku (P/B) | 36.88 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 4 Aug 2026 |
| Margin Keuntungan | 44.76% |
| Margin Operasi (TTM) | 53.44% |
| EPS Cair (TTM) | 3.76 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 35.20% |
| Pertumbuhan Pendapatan Suku Tahunan (YOY) | 53.70% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 318.67% |
| Nisbah Semasa (MRQ) | 8.39 |
| Aliran Tunai Operasi (OCF TTM) | 503.86 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 402.43 M |
| Pulangan Atas Aset (ROA TTM) | 18.50% |
| Pulangan Atas Ekuiti (ROE TTM) | 147.06% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Halozyme Therapeutics, Inc. | Menaik | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 2.0 |
| Aktiviti Orang Dalam | -3.5 |
| Volatiliti Harga | 2.0 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | 4.0 |
| Purata | 1.40 |
|
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. ENHANZE drug delivery technology was introduced with the proprietary enzyme rHuPH20, to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid SC delivery and reduced treatment burden. The company's operations are based in the United States, with minimal long-lived assets located internationally. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 1.11% |
| % Dimiliki oleh Institusi | 101.53% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Snyder Capital Management L P | 31 Mar 2026 | 2,323,077 |
Tiada data dalam julat masa ini.
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| TORLEY HELEN | - | 70.48 | -30,000 | -2,118,900 |
| Jumlah Keseluruhan Kuantiti Bersih | -30,000 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | -2,118,900 | |||
| Purata Pembelian Keseluruhan ($) | - | |||
| Purata Jualan Keseluruhan ($) | 70.48 | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| TORLEY HELEN | Pegawai | 13 May 2026 | Jual automatik (-) | 10,000 | 70.03 | 700,300 |
| TORLEY HELEN | Pegawai | 13 May 2026 | Pelaksanaan pilihan | 10,000 | - | - |
| TORLEY HELEN | Pegawai | 12 May 2026 | Jual automatik (-) | 20,000 | 70.93 | 1,418,600 |
| TORLEY HELEN | Pegawai | 12 May 2026 | Pelaksanaan pilihan | 20,000 | - | - |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |